Kevin Dai

Canaccord downgraded Agios Pharmaceuticals Inc (NASDAQ: AGIO) Thursday from Buy to Hold and cut its price target from $163 to $103. Analysts John Newman and Kevin Dai commented, “Agios announced plans to move AG-881, a dual IDH1 and IDH2 mutation inhibitor, into glioma patients, which...